Loading
Lung Transplant / Pulmonary Hypertension / Protek Solo Transseptal Cannula · Phase 1 Trial
ClinicalTrials.gov · July 31, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a study registration for a Phase 1 trial recruiting 4 participants to evaluate transseptal ECMO as a bridge to lung transplant in patients with pulmonary hypertension and right heart failure. No efficacy or safety results have been posted in this registry record; the trial is currently recruiting.
Phase 1, Interventional, Single Group, Open label, Treatment purpose. Lung Transplant, Pulmonary Hypertension; age from 18 Years; to 80 Years. Intervention: Lung transplant patients. n = 4. 1 site: United States.
This is a study registration for a Phase 1 trial recruiting 4 participants to evaluate transseptal ECMO as a bridge to lung transplant in patients with pulmonary hypertension and right heart failure. No efficacy or safety results have been posted in this registry record; the trial is currently recruiting.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should note this is an early-stage safety study with very limited enrollment. Results are not yet available; readers must await trial completion and peer-reviewed publication before assessing clinical utility.
This is an active Phase 1 trial registration with no results posted; it describes a planned safety study of transseptal ECMO as bridge to lung transplant in a very small cohort.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should note this is an early-stage safety study with very limited enrollment. Results are not yet available; readers must await trial completion and peer-reviewed publication before assessing clinical utility.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06770023). This is a study registration, not published results. Lead sponsor: Mayo Clinic. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 4 participants (ESTIMATED). Conditions: Lung Transplant, Pulmonary Hypertension. Interventions: DEVICE: Protek Solo Transseptal Cannula. Primary outcome measures: Survival until transplant , 3 weeks. Brief summary: The purpose of this study is to determine if transseptal extra-corporeal membrane oxygenation (ECMO) can bridge pulmonary hypertension- right heart failure (PH-RVF) patients to lung transplant safely.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.